PubMed

Impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individuals.

Clifford DB, Evans S, Yang Y, Acosta EP, Goodkin K, Tashima K, Simpson D, Dorfman D, Ribaudo H, Gulick RM.

Ann Intern Med. 2005 Nov 15;143(10):714-21.PMID: 16287792 [PubMed - indexed for MEDLINE]Related articlesFree article

Quality of life, emotional status, and adherence of HIV-1-infected patients treated with efavirenz versus protease inhibitor-containing regimens.

Fumaz CR, Tuldrà A, Ferrer MJ, Paredes R, Bonjoch A, Jou T, Negredo E, Romeu J, Sirera G, Tural C, Clotet B.

J Acquir Immune Defic Syndr. 2002 Mar 1;29(3):244-53.PMID: 11873073 [PubMed - indexed for MEDLINE]Related articles

Summaries for patients. Neuropsychological side effects of efavirenz.

[No authors listed]

Ann Intern Med. 2005 Nov 15;143(10):I43. No abstract available. PMID: 16287787 [PubMed - indexed for MEDLINE]Related articlesFree article

Stepped-dose versus full-dose efavirenz for HIV infection and neuropsychiatric adverse events: a randomized trial.

Gutiérrez-Valencia A, Viciana P, Palacios R, Ruiz-Valderas R, Lozano F, Terrón A, Rivero A, López-Cortés LF; Sociedad Andaluza de Enfermedades Infecciosas.

Ann Intern Med. 2009 Aug 4;151(3):149-56. Epub 2009 Jul 6.PMID: 19581631 [PubMed - indexed for MEDLINE]Related articles

Prediction of neuropsychiatric adverse events associated with long-term efavirenz therapy, using plasma drug level monitoring.

Gutiérrez F, Navarro A, Padilla S, Antón R, Masiá M, Borrás J, Martín-Hidalgo A.

Clin Infect Dis. 2005 Dec 1;41(11):1648-53. Epub 2005 Oct 19.PMID: 16267739 [PubMed - indexed for MEDLINE]Related articles

Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients.

Marzolini C, Telenti A, Decosterd LA, Greub G, Biollaz J, Buclin T.

AIDS. 2001 Jan 5;15(1):71-5.PMID: 11192870 [PubMed - indexed for MEDLINE]Related articles

Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study.

Haas DW, Ribaudo HJ, Kim RB, Tierney C, Wilkinson GR, Gulick RM, Clifford DB, Hulgan T, Marzolini C, Acosta EP.

AIDS. 2004 Dec 3;18(18):2391-400.PMID: 15622315 [PubMed - indexed for MEDLINE]Related articles

Long-term neuropsychiatric disorders on efavirenz-based approaches: quality of life, psychologic issues, and adherence.

Fumaz CR, Muñoz-Moreno JA, Moltó J, Negredo E, Ferrer MJ, Sirera G, Pérez-Alvarez N, Gómez G, Burger D, Clotet B.

J Acquir Immune Defic Syndr. 2005 Apr 15;38(5):560-5.PMID: 15793366 [PubMed - indexed for MEDLINE]Related articles

Three- vs four-drug antiretroviral regimens for the initial treatment of HIV-1 infection: a randomized controlled trial.

Gulick RM, Ribaudo HJ, Shikuma CM, Lalama C, Schackman BR, Meyer WA 3rd, Acosta EP, Schouten J, Squires KE, Pilcher CD, Murphy RL, Koletar SL, Carlson M, Reichman RC, Bastow B, Klingman KL, Kuritzkes DR; AIDS Clinical Trials Group (ACTG) A5095 Study Team.

JAMA. 2006 Aug 16;296(7):769-81.PMID: 16905783 [PubMed - indexed for MEDLINE]Related articlesFree article

Preliminary data of a prospective study on neuropsychiatric side effects after initiation of efavirenz.

Blanch J, Martínez E, Rousaud A, Blanco JL, García-Viejo MA, Peri JM, Mallolas J, De Lazzari E, De Pablo J, Gatell JM.

J Acquir Immune Defic Syndr. 2001 Aug 1;27(4):336-43.PMID: 11468421 [PubMed - indexed for MEDLINE]Related articles

Safety and tolerance of efavirenz in different antiretroviral regimens: results from a national multicenter prospective study in 1,033 HIV-infected patients.

Pérez-Molina JA.

HIV Clin Trials. 2002 Jul-Aug;3(4):279-86.PMID: 12187501 [PubMed - indexed for MEDLINE]Related articlesFree article

Changes in sleep quality and brain wave patterns following initiation of an efavirenz-containing triple antiretroviral regimen.

Moyle G, Fletcher C, Brown H, Mandalia S, Gazzard B.

HIV Med. 2006 May;7(4):243-7.PMID: 16630036 [PubMed - indexed for MEDLINE]Related articles

Comparison of neuropsychiatric side effects in an observational cohort of efavirenz- and protease inhibitor-treated patients.

Hawkins T, Geist C, Young B, Giblin A, Mercier RC, Thornton K, Haubrich R.

HIV Clin Trials. 2005 Jul-Aug;6(4):187-96.PMID: 16214735 [PubMed - indexed for MEDLINE]Related articles

Incidence and risk factors of rash associated with efavirenz in HIV-infected patients with preceding nevirapine-associated rash.

Manosuthi W, Thongyen S, Chumpathat N, Muangchana K, Sungkanuparph S.

HIV Med. 2006 Sep;7(6):378-82.PMID: 16903982 [PubMed - indexed for MEDLINE]Related articles

[Apropos of atypical melancholia with Sustiva (efavirenz)]

Lang JP, Halleguen O, Picard A, Lang JM, Danion JM.

Encephale. 2001 May-Jun;27(3):290-3. French. PMID: 11488260 [PubMed - indexed for MEDLINE]Related articles

Simplification therapy with once-daily didanosine, tenofovir and efavirenz in HIV-1-infected adults with viral suppression receiving a more complex antiretroviral regimen: final results of the EFADITE trial.

Barrios A, Negredo E, Domingo P, Estrada V, Labarga P, Asensi V, Morales D, Santos J, Clotet B, Soriano V; EFADITE Study Group.

Antivir Ther. 2005;10(7):825-32.PMID: 16312178 [PubMed - indexed for MEDLINE]Related articles

Population pharmacokinetics and effects of efavirenz in patients with human immunodeficiency virus infection.

Csajka C, Marzolini C, Fattinger K, Décosterd LA, Fellay J, Telenti A, Biollaz J, Buclin T.

Clin Pharmacol Ther. 2003 Jan;73(1):20-30.PMID: 12545140 [PubMed - indexed for MEDLINE]Related articles

Long-term body fat outcomes in antiretroviral-naive participants randomized to nelfinavir or efavirenz or both plus dual nucleosides. Dual X-ray absorptiometry results from A5005s, a substudy of Adult Clinical Trials Group 384.

Dubé MP, Komarow L, Mulligan K, Grinspoon SK, Parker RA, Robbins GK, Roubenoff R, Tebas P; Adult Clinical Trials Group 384.

J Acquir Immune Defic Syndr. 2007 Aug 15;45(5):508-14.PMID: 17589373 [PubMed - indexed for MEDLINE]Related articles

Long-term assessment of neuropsychiatric adverse reactions associated with efavirenz.

Lochet P, Peyrière H, Lotthé A, Mauboussin JM, Delmas B, Reynes J.

HIV Med. 2003 Jan;4(1):62-6.PMID: 12534961 [PubMed - indexed for MEDLINE]Related articles

Gynaecomastia in HIV-infected men on highly active antiretroviral therapy: association with efavirenz and didanosine treatment.

Mira JA, Lozano F, Santos J, Ramayo E, Terrón A, Palacios R, León EM, Márquez M, Macías J, Fernández-Palacin A, Gómez-Mateos J, Pineda JA; Grupo Andaluz para el Estudio de las Enfermedades Infecciosas.

Antivir Ther. 2004 Aug;9(4):511-7.PMID: 15456082 [PubMed - indexed for MEDLINE]Related articles